GNVC SEC Filings - GenVec, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

934473

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GenVec, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

June 26, 2017	15-12G	GenVec 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-24469 GenVec, Inc. (Exact name of registrant as specified in its charter
June 16, 2017	S-8 POS	GenVec S-8 POS S-8 POS As filed with the U.S. Securities and Exchange Commission on June 16, 2017 Registration No. 333-183182 Registration No. 333-183179 Registration No. 333-176215 Registration No. 333-153693 Registration No. 333-110446 Registration No. 333-208105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183
June 16, 2017	S-8 POS	GenVec S-8 POS S-8 POS As filed with the U.S. Securities and Exchange Commission on June 16, 2017 Registration No. 333-183182 Registration No. 333-183179 Registration No. 333-176215 Registration No. 333-153693 Registration No. 333-110446 Registration No. 333-208105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183
June 16, 2017	S-8 POS	GenVec S-8 POS S-8 POS As filed with the U.S. Securities and Exchange Commission on June 16, 2017 Registration No. 333-183182 Registration No. 333-183179 Registration No. 333-176215 Registration No. 333-153693 Registration No. 333-110446 Registration No. 333-208105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183
June 16, 2017	S-8 POS	GenVec S-8 POS S-8 POS As filed with the U.S. Securities and Exchange Commission on June 16, 2017 Registration No. 333-183182 Registration No. 333-183179 Registration No. 333-176215 Registration No. 333-153693 Registration No. 333-110446 Registration No. 333-208105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183
June 16, 2017	S-8 POS	GenVec S-8 POS S-8 POS As filed with the U.S. Securities and Exchange Commission on June 16, 2017 Registration No. 333-183182 Registration No. 333-183179 Registration No. 333-176215 Registration No. 333-153693 Registration No. 333-110446 Registration No. 333-208105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183
June 16, 2017	S-8 POS	GenVec S-8 POS S-8 POS As filed with the U.S. Securities and Exchange Commission on June 16, 2017 Registration No. 333-183182 Registration No. 333-183179 Registration No. 333-176215 Registration No. 333-153693 Registration No. 333-110446 Registration No. 333-208105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183
June 16, 2017	RW	GenVec RW RW GenVec, Inc. 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 (240) 632-0740 June 16, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Request for Withdrawal of GenVec, Inc. Registration Statement on Form S-3 (File No. 333-213478) Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as ame
June 16, 2017	EX-3.1	TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENVEC, INC. EX-3.1 2 d372393dex31.htm EX-3.1 Exhibit 3.1 TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENVEC, INC. First: The name of this Corporation is GenVec, Inc. Second: The registered office of the Corporation in the State of Delaware is to be located at Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Zip Code 19801. The registered agent in ch
June 16, 2017	EX-3.2	GENVEC, INC. * * * * * AMENDED AND RESTATED BYLAWS * * * * * ARTICLE I EX-3.2 Exhibit 3.2 GENVEC, INC. * * * * * AMENDED AND RESTATED BYLAWS * * * * * ARTICLE I OFFICES Section 1. The registered office of the corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. The corporation may also have offices at such other places both within and without the State of Delaware as the board of directors may from time to time determine
June 16, 2017	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 d372393d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2017 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware 000-24469 23-2705690 (State or other jurisdiction of incorporation) (
June 15, 2017	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2017 GenVec, Inc.
May 17, 2017	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2017 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-2705690
May 12, 2017	DEFM14A	GenVec DEFM14A DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2017	10-Q	GNVC / GenVec, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-24469 GenVec, Inc
March 14, 2017	SC 13G/A	GNVC / GenVec, Inc. / MMCAP International Inc. SPC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G AMENDMENT NO.
March 6, 2017	EX-10.29	FIRST AMENDMENT TO LEASE AGREEMENT EX-10.29 3 t1700563ex10-29.htm EXHIBIT 10.29 Exhibit 10.29 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (“this First Amendment”) is dated as of December 19, 2014 (“Effective Date”), by and between ARE-MARYLAND NO. 30, LLC, a Maryland limited liability company, having an address at 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), and GENVEC, I
March 6, 2017	EX-10.31	THIRD AMENDMENT TO LEASE AGREEMENT EX-10.31 5 t1700563ex10-31.htm EXHIBIT 10.31 Exhibit 10.31 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (“this Third Amendment”) is dated as of July 27, 2015 (“Effective Date”), by and between ARE-MARYLAND NO. 30, LLC, a Maryland limited liability company, having an address at 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), and GENVEC, INC.,
March 6, 2017	EX-24.1	GENVEC, INC. Power of Attorney EX-24.1 8 t1700563ex24-1.htm EXHIBIT 24.1 EXHIBIT 24.1 GENVEC, INC. Power of Attorney KNOW ALL MEN BY THESE PRESENTS that each of the undersigned officers and directors of GenVec, Inc., a Delaware corporation (the “Corporation”), hereby constitutes and appoints Douglas J. Swirsky and James V. Lambert the true and lawful agents and attorneys-in-fact of the undersigned with full power of substitutio
March 6, 2017	EX-10.28	LEASE AGREEMENT EX-10.28 2 t1700563ex10-28.htm EXHIBIT 10.28 Exhibit 10.28 LEASE AGREEMENT THIS LEASE AGREEMENT (“this Lease”) is made as of this 15th day of November, 2013, between ARE-MARYLAND NO. 30, LLC, a Maryland limited liability company (“Landlord”), and GENVEC, INC., a Delaware corporation (“Tenant”). BASIC LEASE PROVISIONS Address: Suite 220N, 910 Clapper Road, Gaithersburg, Maryland 20878. Premises: Th
March 6, 2017	EX-10.30	SECOND AMENDMENT TO LEASE AGREEMENT Exhibit 10.30 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (“this Second Amendment”) is dated as of February 11, 2015 (“Effective Date”), by and between ARE-MARYLAND NO. 30, LLC, a Maryland limited liability company, having an address at 385 E. Colorado Blvd., Suite 299, Pasadena, California 91101 (“Landlord”), and GENVEC, INC., a Delaware corporation, having an add
March 6, 2017	10-K	GNVC / GenVec, Inc. FORM 10-K (Annual Report) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-2
February 16, 2017	SC 13G	GNVC / GenVec, Inc. / MMCAP International Inc. SPC Passive Investment SC 13G 1 mmcap-genvec13g021517.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 GENVEC, INC. (Name of Issuer) COMMON STOCK, par value $0.001 (Title of Class of Securities) 37246C406 (CUSIP Number) February 2, 2017 (Date of Event Which Requires Filing of This Statement) Check th
February 14, 2017	SC 13G/A	GNVC / GenVec, Inc. / Frigate Ventures LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Amendment No.
February 14, 2017	SC 13G/A	GNVC / GenVec, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GenVec, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 37246C307 (CUSIP Number) December 31, 201
February 8, 2017	SC 13G/A	GNVC / GenVec, Inc. / INTRACOASTAL CAPITAL, LLC - SC 13G AMENDMENT NO. 1 Passive Investment SC 13G/A 1 d286859dsc13ga.htm SC 13G AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 37246C07 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) C
January 31, 2017	SC 13G	GNVC / GenVec, Inc. / Aristides Capital LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GenVec, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 37246C307 (CUSIP Number) January 24, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 24, 2017	EX-4.1	AMENDMENT NO. 1 TO RIGHTS AGREEMENT Exhibit 4.1 Execution Copy AMENDMENT NO. 1 TO RIGHTS AGREEMENT THIS AMENDMENT NO. 1 TO THE RIGHTS AGREEMENT (this ?Amendment?) is made as of this 24th day of January, 2017 (the ?Amendment Effective Date?), by and between GenVec, Inc., a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Company, LLC (the ?Rights Agent?) to amend that certain Rights Agreement, dated as of Aug
January 24, 2017	EX-99.1	Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec’s AdenoVerse™ to be Integrated into Intrexon's Proprietary Synthetic Biology Platform EX-99.1 4 t1700040ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec’s AdenoVerse™ to be Integrated into Intrexon's Proprietary Synthetic Biology Platform GERMANTOWN, MD, and GAITHERSBURG, MD, Jan. 24, 2017 - Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of
January 24, 2017	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among INTREXON CORPORATION, Intrexon GV Holding, Inc. GENVEC, INC. Dated as of January 24, 2017 TABLE OF CONTENTS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among INTREXON CORPORATION, Intrexon GV Holding, Inc. and GENVEC, INC. Dated as of January 24, 2017 TABLE OF CONTENTS Page Article 1 The Merger 2 1.1 The Merger 2 1.2 Closing and Effective Time of the Merger 3 Article 2 Conversion of Securities IN THE MERGER 3 2.1 Conversion of Securities 3 2.2 Payment for Securities; Surrender of Certificates 4 2.3
January 24, 2017	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events 8-K 1 t17000408k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (C
January 24, 2017	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among INTREXON CORPORATION, Intrexon GV Holding, Inc. GENVEC, INC. Dated as of January 24, 2017 TABLE OF CONTENTS EX-2.1 2 t1700040ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among INTREXON CORPORATION, Intrexon GV Holding, Inc. and GENVEC, INC. Dated as of January 24, 2017 TABLE OF CONTENTS Page Article 1 The Merger 2 1.1 The Merger 2 1.2 Closing and Effective Time of the Merger 3 Article 2 Conversion of Securities IN THE MERGER 3 2.1 Conversion of Securities 3 2.2 Payment for Secur
January 24, 2017	EX-4.1	AMENDMENT NO. 1 TO RIGHTS AGREEMENT EX-4.1 3 t1700040ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Execution Copy AMENDMENT NO. 1 TO RIGHTS AGREEMENT THIS AMENDMENT NO. 1 TO THE RIGHTS AGREEMENT (this “Amendment”) is made as of this 24th day of January, 2017 (the “Amendment Effective Date”), by and between GenVec, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Rights Agent”) to amend that ce
January 24, 2017	DEFA14A	GenVec FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-2705
January 24, 2017	EX-99.1	Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec’s AdenoVerse™ to be Integrated into Intrexon's Proprietary Synthetic Biology Platform Exhibit 99.1 Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec?s AdenoVerse? to be Integrated into Intrexon's Proprietary Synthetic Biology Platform GERMANTOWN, MD, and GAITHERSBURG, MD, Jan. 24, 2017 - Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today annou
January 24, 2017	EX-99.1	Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec’s AdenoVerse™ to be Integrated into Intrexon’s Proprietary Synthetic Biology Platform EX-99.1 2 d330527dex991.htm EX-99.1 Exhibit 99.1 Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec’s AdenoVerse™ to be Integrated into Intrexon’s Proprietary Synthetic Biology Platform GERMANTOWN, MD, and GAITHERSBURG, MD, Jan. 24, 2017 — Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life a
January 24, 2017	425	GenVec 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 INTREXON CORPORATION (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commissi
December 16, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270
December 1, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events 8-K 1 t16007798k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (C
December 1, 2016	EX-99.1	GENVEC EFFECTS 1-FOR-10 REVERSE STOCK SPLIT Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com GENVEC EFFECTS 1-FOR-10 REVERSE STOCK SPLIT GAITHERSBURG, MD - December 1, 2016 - GenVec, Inc. (NASDAQ: GNVC) (?GenVec? or ?the Company?) announced that the Company?s previously declared one-for-ten reverse stock split of its outstanding shares of common stock (the ?Reverse Stock Spl
December 1, 2016	EX-3.1	CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENVEC, INC. Under Section 242 of the General Corporation Law of the State of Delaware EX-3.1 2 t1600779ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENVEC, INC. Under Section 242 of the General Corporation Law of the State of Delaware GENVEC, INC., a corporation duly organized and existing under the Delaware General Corporation Law (the “Corporation”), does hereby certify: 1. The name of the Corporation is GE
November 16, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270
November 4, 2016	10-Q	GenVec FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-24469 GenVec,
November 4, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 t16007108k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (C
November 4, 2016	EX-99.1	GENVEC REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS GAITHERSBURG, MD - November 4, 2016 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the third quarter ended September 30, 2016. For the three months ended September 30, 2016, the company repo
October 24, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-2705
October 7, 2016	CORRESP	GenVec ESP Hogan Lovells US LLP Harbor East 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www.
September 12, 2016	DEF 14A	GenVec DEFINITIVE PROXY STATEMENT t1602096-def14a - block - 4.4664466s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐
September 2, 2016	S-3	GenVec FORM S-3 As Filed with the Securities and Exchange Commission on September 2, 2016 Registration No.
September 1, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-27056
August 26, 2016	PRE 14A	GenVec PRELIMINARY PROXY STATEMENT t1602026-pre14a - none - 4.1314131s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?
August 26, 2016	PRE 14A	GenVec PRELIMINARY PROXY STATEMENT t1602026-pre14a - none - 4.1314131s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?
August 24, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-27056
August 24, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-27056
August 5, 2016	10-Q	GenVec FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-24469 GenVec, Inc.
August 5, 2016	EX-99.1	GENVEC REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS GAITHERSBURG, MD - August 5, 2016 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the second quarter ended June 30, 2016. For the three months ended June 30, 2016, the company reported a net
August 5, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 t16005038k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Com
July 27, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 t16004638k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Comm
July 27, 2016	EX-99.1	FDA liftS clinical hold on CGF166 Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE FDA liftS clinical hold on CGF166 GAITHERSBURG, MD, July 25, 2016 – GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it was notified by its collaborator, Novartis, that the Food and Drug Administration (FDA) has lifted th
June 2, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware 000-24469 23-2705690 (state or other jurisdiction of (Commission (I.R.S. Employer incorporati
June 2, 2016	EX-16.1	June 1, 2016 EX-16.1 2 t1600378ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 June 1, 2016 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read GenVec, Inc.’s (the “Company”) disclosure set forth in Item 4.01(a), “Changes in Registrant’s Certifying Accountant”, in its Current Report on Form 8-K dated June 1, 2016 and are in agreement with such statements concer
May 18, 2016	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d149978dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value, of GenVec Inc., a Delaware corporation, and fu
May 18, 2016	SC 13G	GNVC / GenVec, Inc. / Frigate Ventures LP - SC 13G Passive Investment SC 13G 1 d149978dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37246C307 (CUSIP Number) May 5, 2016 (Date of Ev
May 12, 2016	10-Q	GenVec FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-24469 GenVec, Inc
May 12, 2016	EX-99.1	GENVEC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS GAITHERSBURG, MD - May 12, 2016 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2016. For the three months ended March 31, 2016, the company reported a net l
May 12, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 t16003258k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware 000-24469 23-2705690 (state or other jurisdiction of (Commissio
May 12, 2016	SC 13G	GenVec SC 13G (Passive Acquisition of More Than 5% of Shares) SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 37246C307 (CUSIP Number) May 4, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
May 10, 2016	EX-4.1	COMMON STOCK PURCHASE WARRANT GENVEC, inc. EX-4.1 3 t1601290ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFER
May 10, 2016	EX-10.1	SECURITIES PURCHASE AGREEMENT EX-10.1 5 t1601290ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 4, 2016, between GenVec, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject
May 10, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 t16012908k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware 000-24469 23-2705690 (state or other jurisdiction of (Commission
May 10, 2016	EX-1.1	430 Park Avenue \| New York, New York 10022 \| 212.356.0500 Security services provided by H.C. Wainwright & Co., LLC \| Member: FINRA/SIPC EX-1.1 2 t1601290ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 May 4, 2016 STRICTLY CONFIDENTIAL GenVec, Inc. 910 Clopper Road, Suite 220N Gaithersburg, Maryland 20878 Attn: Douglas Swirsky Dear Sirs: This letter agreement (this “Agreement”) constitutes the agreement between GenVec, Inc. (the “Company”) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”), that Rodman shall serve as the exclu
May 6, 2016	424B5	UP TO $75,000,000 OF OUR COMMON STOCK PREFERRED STOCK WARRANTS TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUMMARY RISK FACTORS SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS USE OF PROCEEDS PLAN OF DISTRIBUTION DESCRIPTION OF COMMON STOCK DESCRIPTION Filed pursuant to Rule 424(b)(5) Registration File No. 333-193511 PROSPECTUS SUPPLEMENT To prospectus dated February 11, 2014 5,471,957 SHARES OF COMMON STOCK Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 5,471,957 shares of our common stock, $0.001 par value per share, at a price of $0.91375 per share, to selected investors pursuant to this prospectus sup
May 2, 2016	EX-99.1	GenVec Provides Update on Hearing Loss Clinical Program Data Safety Monitoring Board Recommends Trial Continue Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GenVec Provides Update on Hearing Loss Clinical Program Data Safety Monitoring Board Recommends Trial Continue GAITHERSBURG, MD – May 2, 2016 – GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it was notified by its colla
May 2, 2016	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-2705690 (
March 9, 2016	10-K	GenVec FORM 10-K (Annual Report) 10-K 1 t160010210k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. COMMISSION FIL
March 9, 2016	EX-99.1	GENVEC REPORTS FOURTH QUARTER AND 2015 YEAR-END FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS FOURTH QUARTER AND 2015 YEAR-END FINANCIAL RESULTS GAITHERSBURG, MD - March 9, 2016 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2015. For the year ended December 31, 2015, the c
March 9, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 t16001368k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Comm
March 9, 2016	EX-10.10	GENVEC, INC. 2015 OMNIBUS INCENTIVE PLAN DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT COVER SHEET Exhibit 10.10 Option No.: GENVEC, INC. 2015 OMNIBUS INCENTIVE PLAN DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT COVER SHEET GenVec, Inc., a Delaware corporation (the “Company”), hereby grants an Option (the “Option”) to purchase shares of its common stock, par value $0.001 per share (the “Stock”), to the individual named below as the Grantee. The terms and conditions of the Option are set forth i
March 9, 2016	EX-10.33	AMENDMENT NO. 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT Exhibit 10.33 AMENDMENT NO. 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment No. 1 to Research Collaboration and License Agreement (this “Amendment”) is made as of this 10th day of November 2015 (the “Effective Date”), by and between GenVec, Inc., a Delaware corporation (“GenVec”) and Novartis Institutes for Biomedical Research, Inc., a Delaware corporation (“Novartis”), and amends
March 9, 2016	EX-24.1	GENVEC, INC. Power of Attorney EX-24.1 7 t1600102ex24-1.htm EXHIBIT 24.1 EXHIBIT 24.1 GENVEC, INC. Power of Attorney KNOW ALL MEN BY THESE PRESENTS that each of the undersigned officers and directors of GenVec, Inc., a Delaware corporation (the “Corporation”), hereby constitutes and appoints Douglas J. Swirsky and James V. Lambert the true and lawful agents and attorneys-in-fact of the undersigned with full power of substitutio
March 9, 2016	EX-10.8	GENVEC, INC. 2015 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT COVER SHEET Exhibit 10.8 Option No.: GENVEC, INC. 2015 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT COVER SHEET GenVec, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.001 per share (the “Stock”), to the individual named below as the Grantee. The terms and conditions of the Option are set forth in this cover s
March 9, 2016	EX-10.9	GENVEC, INC. 2015 OMNIBUS INCENTIVE PLAN DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT COVER SHEET EX-10.9 3 t1600102ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 Option No.: GENVEC, INC. 2015 OMNIBUS INCENTIVE PLAN DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT COVER SHEET GenVec, Inc., a Delaware corporation (the “Company”), hereby grants an Option (the “Option”) to purchase shares of its common stock, par value $0.001 per share (the “Stock”), to the individual named below as the Grantee. The terms and
February 26, 2016	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2016 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270
February 16, 2016	SC 13G/A	GNVC / GenVec, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 GenVen Inc (Name of Issuer) Common Stock (Title of Class of Securities) 37246C307 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 16, 2016	SC 13G/A	GNVC / GenVec, Inc. / Cormorant Global Healthcare Master Fund, LP Passive Investment SC 13G/A 1 a6997913ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GenVec, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 37246C307 (CUSI
January 22, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 t16000168k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2016 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission
January 22, 2016	EX-99.1	GenVec Provides Investor Update Highlights Ongoing Initiatives Involving the AdenoVerse™ Gene Delivery Platform EX-99.1 2 t1600016ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GenVec Provides Investor Update Highlights Ongoing Initiatives Involving the AdenoVerse™ Gene Delivery Platform GAITHERSBURG, MD – January 20, 2016 – GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, p
January 15, 2016	SC 13G/A	GNVC / GenVec, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) GenVec, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 37246C307 (CUSIP Number) January 11, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
January 11, 2016	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2016 (January 8, 2016) GENVEC, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission Fi
November 19, 2015	S-8	GenVec FORM S-8 As filed with the Securities and Exchange Commission on November 19, 2015 Registration No.
November 19, 2015	EX-24.1	GENVEC, INC. POWER OF ATTORNEY Exhibit 24.1 GENVEC, INC. POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned Officers and Directors of GenVec, Inc., a Delaware corporation (the ?Corporation?), hereby constitute and appoint Douglas J. Swirsky the true and lawful agent and attorney-in-fact of the undersigned with full power and authority in said agent and attorney-in-fact to sign for the undersigned and in t
November 16, 2015	EX-3.1	CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENVEC, INC. Under Section 242 of the General Corporation Law of the State of Delaware Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENVEC, INC. Under Section 242 of the General Corporation Law of the State of Delaware GENVEC, INC., a corporation duly organized and existing under the Delaware General Corporation Law (the “Corporation”), does hereby certify: 1. The name of the Corporation is GENVEC, INC. 2. The amendment set forth b
November 16, 2015	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2015 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270
November 16, 2015	EX-10.1	__________________________________________________________________ GenVec, Inc. 2015 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Exhibit 10.1 GenVec, Inc. 2015 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 8 3.1. Committee. 8 3.1.1. Powers and Authorities. 8 3.1.2. Composition of the Committee. 9 3.1.3. Other Committees. 9 3.1.4. Delegation by the Committee. 9 3.2. Board. 10 3.3. Terms of Awards. 10 3.3.1. Committee Authority. 10 3.3.2. Forfeiture; Recoupment. 11 3
November 9, 2015	EX-99.1	GENVEC REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS GAITHERSBURG, MD - November 9, 2015 - GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, reported financial results for the third quarter ended September 30, 2015. For the three months ended S
November 9, 2015	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2015 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-2705
October 6, 2015	DEF 14A	GenVec DEFINITIVE PROXY STATEMENT t1502220-def14a - block - 7.560756s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐
September 18, 2015	PRE 14A	GenVec PRELIMINARY PROXY STATEMENT t1502180-pre14a - none - 7.6227622s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy
August 7, 2015	EX-99.1	GENVEC REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS EXHIBIT 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS GAITHERSBURG, MD - August 7, 2015 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, GenVec reported a net loss
August 7, 2015	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2015 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270569
May 8, 2015	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2015 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 0-24469 (Commission File Number) 23-2705690 (I.
May 8, 2015	EX-99.1	GENVEC REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS GAITHERSBURG, MD - May 8, 2015 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of
April 23, 2015	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2015 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270569
April 22, 2015	EX-24.1	GENVEC, INC. SECTION 16 POWER OF ATTORNEY Unassociated Document GENVEC, INC. SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Douglas J. Swirsky and James V. Lambert, each for so long as he is an officer of GenVec, Inc. (the ?Company?), the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity a
March 24, 2015	8-K	GenVec FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2015 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 0-24469 (Commission File Number) 23-2705690
March 24, 2015	EX-99.1	GENVEC REPORTS FOURTH QUARTER AND 2014 YEAR-END FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS FOURTH QUARTER AND 2014 YEAR-END FINANCIAL RESULTS GAITHERSBURG, MD ? March 24, 2015 ? GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the
February 17, 2015	SC 13G/A	GNVC / GenVec, Inc. / EcoR1 Capital, LLC - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 GenVec, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 37246C 30 7 (CUSIP Number) December
February 17, 2015	SC 13G	GNVC / GenVec, Inc. / PERCEPTIVE ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GenVec Inc (Name of Issuer) Common Stock (Title of Class of Securities) 37246C307 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1
December 9, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders 8-K 1 t809768k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Com
November 12, 2014	EX-99.1	GENVEC REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS GAITHERSBURG, MD – November 12, 2014 – GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the
November 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-270
November 4, 2014	DEF 14A	GNVC / GenVec, Inc. DEF 14A - - DEFINITIVE PROXY STATEMENT TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid
November 3, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-2705
October 29, 2014	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2014 (October 28, 2014) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Emplo
October 21, 2014	PRER14A	GNVC / GenVec, Inc. PRER14A - - PRELIMINARY REVISED PROXY STATEMENT TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid
October 20, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 t805228k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Com
August 29, 2014	PRE 14A	GNVC / GenVec, Inc. PRE 14A - - SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant o Check the appropriate box: þ Preliminary Proxy Statement o Confidential, For Use of
August 12, 2014	EX-99.1	GENVEC REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS GAITHERSBURG, MD - August 12, 2014 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014,
August 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 000-24469 (Commission File Number) 23-27056
June 16, 2014	EX-16.1	June 16, 2014 Exhibit 16.1 June 16, 2014 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for GenVec, Inc. (“GenVec” or the “Company”) and, under the date of March 28, 2014, we reported on the financial statements of the Company as of and for the years ended December 31, 2013 and 2012. On June 11, 2014, we were dismissed. We have read GenVe
June 16, 2014	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 0-24469 (Commission File Number) 23-2705690 (
May 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 0-24469 (Commission File Number) 23-2705690 (I
May 12, 2014	EX-99.1	GENVEC REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS GAITHERSBURG, MD - May 12, 2014 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2014. For the three months ended March 31, 2014, the company reported a net l
March 28, 2014	EX-99.1	GENVEC REPORTS FOURTH QUARTER AND 2013 YEAR-END FINANCIAL RESULTS Exhibit 99.1 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS FOURTH QUARTER AND 2013 YEAR-END FINANCIAL RESULTS GAITHERSBURG, MD - March 28, 2014 - GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the
March 28, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 0-24469 (Commission File Number) 23-2705690
March 28, 2014	10-K	GenVec 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-24469 GENVEC, INC. (
March 25, 2014	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 cormorantgenvec-ex991.htm JOINT FILER AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of March 25, 2014, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen (collectively, the "Filers"). Each of the Filers may be required to file with the United States Securiti
March 25, 2014	SC 13G	GNVC / GenVec, Inc. / Cormorant Asset Management, LLC - SCHEDULE 13G (MARCH 2014) Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GenVec, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 37246C307 (CUSIP Number) March 17, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
March 18, 2014	EX-1.1	GENVEC, INC. 2,870,000 Shares of Common Stock, par value $0.001 per share PLACEMENT AGENCY AGREEMENT EX-1.1 2 v372019ex1-1.htm EXHIBIT 1.1 GENVEC, INC. 2,870,000 Shares of Common Stock, par value $0.001 per share PLACEMENT AGENCY AGREEMENT March 13, 2014 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, California 92660 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Dear Sir or Madam: GenVec, Inc., a Delaware corporation (the “Company”), proposes to issue and s
March 18, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3720198k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 0-24469 (Commission
March 18, 2014	EX-10.1	SCHEDULE I SCHEDULE OF INVESTORS March 13, 2014 GenVec, Inc. 65 West Watkins Mill Road Gaithersburg, MD 20878 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms and agrees with you as follows: 1. This Purchase Agreement (the “Agreement”) is made as of the date hereof between GenVec, Inc., a Delaware corporation (the “Company”), and the Investor that is a signatory to this Agreement. 2. The Company has authoriz
March 14, 2014	424B5	SUBJECT TO COMPLETION, DATED MARCH 12, 2014 SHARES OF COMMON STOCK TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENT SUMMARY THE OFFERING RISK FACTORS SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS USE OF PROCEEDS DILUTION P The information in this preliminary prospectus supplement is not complete and may be changed.
March 14, 2014	424B5	2,870,000 SHARES OF COMMON STOCK TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENT SUMMARY THE OFFERING RISK FACTORS SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS USE OF PROCEEDS DILUTION PLAN OF DISTRIBUTION INCORPORATION Filed pursuant to Rule 424(b)(5) Registration File No. 333-193511 PROSPECTUS SUPPLEMENT To prospectus dated February 11, 2014 2,870,000 SHARES OF COMMON STOCK Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 2,870,000 shares of our common stock, $0.001 par value per share, at a price of $3.15 per share. Our common stock is listed on the NASDAQ Capital Market
February 26, 2014	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (state or other jurisdiction of incorporation) (Commission (I.R.S. Em
February 21, 2014	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G, as amended, dated February 21, 2014 with respect to the shares of Common Stock of GenVec, Inc. and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the S
February 21, 2014	SC 13G/A	GNVC / GenVec, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 GenVec, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 37246C 30 7 (CUSIP Number) February 1, 2014 (Da
February 14, 2014	SC 13G/A	GNVC / GenVec, Inc. / Biotechnology Value Fund L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37246C 30 7 (CUSIP Number) December 31, 2013 (
February 13, 2014	424B5	UP TO $10,000,000 OF SHARES OF COMMON STOCK Roth Capital Partners TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT SUMMARY THE OFFERING RISK FACTORS USE OF PROCEEDS DILUTION PLAN OF DISTRIBUTION INCORPORATION OF CERTAIN INFORMATION BY REFERENCE WHE Filed pursuant to Rule 424(b)(5) Registration File No. 333-193511 PROSPECTUS SUPPLEMENT To prospectus dated February 11, 2014 UP TO $10,000,000 OF SHARES OF COMMON STOCK We are offering up to $10.0 million of shares of our common stock from time to time through our sales agent, Roth Capital Partners, LLC (“Roth”). These sales, if any, will be made pursuant to the Equity Distribution Agreement, or
February 13, 2014	EX-1.1	GENVEC, INC. Common Stock EQUITY DISTRIBUTION AGREEMENT GENVEC, INC. Common Stock EQUITY DISTRIBUTION AGREEMENT February 11, 2014 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Ladies and Gentlemen: GenVec, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (“Roth”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time durin
February 13, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2014 GenVec, Inc. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (state or other jurisdiction of (Commission (I.R.S. Employer incorpor
February 10, 2014	CORRESP	- Hogan Lovells US LLP 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www.
February 10, 2014	CORRESP	- GENVEC, INC. 910 Clopper Road, Suite 220N Gaithersburg, MD 20878 February 10, 2014 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Re: GenVec, Inc. Shelf Registration Statement on Form S-3 (File No. 333-193511) Request for Acceleration of Effective Date Dear Mr. Riedler: Pursuant to Rule 461 of the General Rules and Regulations under the
January 23, 2014	S-3	- FORM S-3 As Filed with the Securities and Exchange Commission on January 23, 2014 Registration No.
January 23, 2014	EX-12.1	Statement of Computation of Earnings to Fixed Charges and Preferred Stock Dividends Exhibit 12.1 Statement of Computation of Earnings to Fixed Charges and Preferred Stock Dividends For the Nine Months Ended September 30, For the Year Ended December 31, 2013 2012 2011 2010 2009 2008 (Unaudited) Fixed Charges $ 201 $ 268 $ 268 $ 269 $ 243 $ 294 Breakout of Fixed Charges Interest expensed and capitalized $ - $ - $ - $ - $ 13 $ 60 Amortized premiums, discounts and capitalized expense
December 11, 2013	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporatio
November 27, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporati
November 27, 2013	SC 13G/A	GNVC / GenVec, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37246C 30 7 (CUSIP Number) November 25, 2013 (
November 27, 2013	EX-10.1	Amendment to GenVec, Inc. 2011 Omnibus Incentive Plan Exhibit 10.1 Amendment to GenVec, Inc. 2011 Omnibus Incentive Plan The GenVec, Inc. 2011 Omnibus Incentive Plan (the “Plan”) is hereby amended as follows: 1. Section 4.1 of the Plan is hereby amended in its entirety to read as follows: “Subject to adjustment as provided under the Plan, the total number of shares of Stock that are available for Awards under the Plan shall be equal to the sum of (i)
November 12, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporati
November 12, 2013	EX-99.1	GENVEC REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE GENVEC REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS GAITHERSBURG, MD - November 12, 2013 - GenVec, Inc. (NASDAQ: GNVC) today announced financial results for the third quarter and nine months ended September 30, 2013. Third Quarter and Recent Corporate Highlights ·
October 21, 2013	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2013 (October 13, 2013) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Emplo
October 16, 2013	DEF 14A	- FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of
October 7, 2013	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation
September 19, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Shareholder Director Nominations - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporat
September 18, 2013	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g0954300209102013.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 18, 2013 with respect to the shares of Common Stock of GenVec, Inc. and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance
September 18, 2013	SC 13G	GNVC / GenVec, Inc. / EcoR1 Capital, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 GenVec, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 37246C 30 7 (CUSIP Number) September 10, 2013 (D
September 5, 2013	EX-99.1	GenVec BOARD restructures operations and Withdraws plan of Dissolution CEO Cynthia Collins to leave Company effective immediately; and CFO Douglas Swirsky to assume role of CEO Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 [email protected] Institutional Investor Contact: S.A. Noonan Communications Susan A. Noonan (212) 966-3650 [email protected] GenVec BOARD restructures operations and Withdraws plan
September 5, 2013	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporati
August 8, 2013	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
August 8, 2013	PREM14A	- PREM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
July 30, 2013	8-K	Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
June 28, 2013	8-K	Costs Associated with Exit or Disposal Activities - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
June 25, 2013	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
June 24, 2013	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2013 (June 24, 2013) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of
May 28, 2013	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2013 (May 24, 2013) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of I
April 26, 2013	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2013 (April 25, 2013) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer
March 22, 2013	EX-99.1	GENVEC REPORTS FOURTH QUARTER AND 2012 YEAR-END FINANCIAL RESULTS 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.
March 22, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
February 14, 2013	SC 13G/A	GNVC / GenVec, Inc. / BIOTECHNOLOGY VALUE FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37246C 30 7 (CUSIP Number) December 31, 2012 (
February 12, 2013	8-K	Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2013 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporati
February 8, 2013	8-K	Results of Operations and Financial Condition, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2013 (February 7, 2013) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Emplo
November 9, 2012	EX-99.1	GENVEC REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS EXHIBIT 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 [email protected] Institutional Investor Contact: S.A. Noonan Communications Susan A. Noonan (212) 966-3650 [email protected] GENVEC REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS GA
November 9, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporatio
October 2, 2012	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2012 (September 29, 2012) GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Empl
October 2, 2012	EX-99.1	GENVEC ENTERS INTO $3.5 MILLION CONTRACT WITH NAVAL MEDICAL RESEARCH CENTER TO ADVANCE MALARIA PROGRAM EX-99.1 2 v324864ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: Institutional Investor Contact: GenVec, Inc. S.A. Noonan Communications Douglas J. Swirsky Susan A. Noonan (240) 632-5510 (212) 966-3650 [email protected] [email protected] GENVEC ENTERS
September 25, 2012	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporat
September 25, 2012	EX-99.1	GENVEC ANNOUNCES REDUCTION IN WORKFORCE Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: Institutional Investor Contact: GenVec, Inc. S.A. Noonan Communications Douglas J. Swirsky Susan A. Noonan (240) 632-5510 (212) 966-3650 [email protected] [email protected] GENVEC ANNOUNCES REDUCTION IN WORKFORCE GAITHERSBURG,
August 9, 2012	EX-24.1	GENVEC, INC. POWER OF ATTORNEY GENVEC, INC. POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned Officers and Directors of GenVec, Inc., a Delaware corporation (the “Corporation”), hereby constitute and appoint Cynthia Collins and Douglas J. Swirsky, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and a
August 9, 2012	EX-99.1	GENVEC REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS EX-99.1 2 v320734ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: Institutional Investor Contact: GenVec, Inc. S.A. Noonan Communications Douglas J. Swirsky Susan A. Noonan (240) 632-5510 (212) 966-3650 [email protected] [email protected] GENVEC REPORT
August 9, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
August 9, 2012	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on August 9, 2012 Registration No.
August 9, 2012	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on August 9, 2012 Registration No.
August 9, 2012	EX-24.1	GENVEC, INC. POWER OF ATTORNEY GENVEC, INC. POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned Officers and Directors of GenVec, Inc., a Delaware corporation (the “Corporation”), hereby constitute and appoint Cynthia Collins and Douglas J. Swirsky, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said agents and attorneys-in-fact, and a
July 17, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
July 17, 2012	EX-10.1	Amendment to GenVec, Inc. 2011 Omnibus Incentive Plan Amendment to GenVec, Inc. 2011 Omnibus Incentive Plan The GenVec, Inc. 2011 Omnibus Incentive Plan (the “Plan”) is hereby amended as follows: 1. Section 4.1 of the Plan is hereby amended in its entirety to read as follows: Subject to adjustment as provided under the Plan, the total number of shares of Stock that are available for Awards under the Plan shall be equal to the sum of (i) nine hundred
May 31, 2012	DEF 14A	- SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of
May 24, 2012	EX-10.1	Employment Agreement EXHIBIT 10.1 Employment Agreement This Employment Agreement (the “Agreement”) is made and entered into as of May 18, 2012, by and between CYNTHIA COLLINS (the “Executive”) and GenVec, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be employed by the Company on suc
May 24, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation) F
May 24, 2012	EX-10.4	CONSULTING AGREEMENT EXHIBIT 10.4 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of May 22, 2012, by and between GenVec, Inc., a Delaware corporation (the “Company”), and Paul H. Fischer, Ph.D., a resident of the State of Maryland (“Consultant”). As of the date first written above, Consultant is the President and Chief Executive Officer of the Company. Effective as of May
May 24, 2012	EX-10.2	GENVEC, INC. CEO INDUCEMENT AWARD OF A NON-QUALIFIED STOCK OPTION EX-10.2 3 v314403ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Option No.: GENVEC, INC. CEO INDUCEMENT AWARD OF A NON-QUALIFIED STOCK OPTION GenVec, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, par value $.001 (the “Stock”) to the individual named below. The terms and conditions of the option are set forth in this cover sheet and in the attac
May 24, 2012	EX-10.5	GENVEC, INC. 2011 OMNIBUS INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT EX-10.5 6 v314403ex10-5.htm EXHIBIT 10.5 EXHIBIT 10.5 Option No.: GENVEC, INC. 2011 OMNIBUS INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT GenVec, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, par value $.001 (the “Stock”) to the individual named below. The terms and conditions of the option are set forth in this cover sheet and
May 24, 2012	EX-10.3	SEPARATION AND RELEASE AGREEMENT EXHIBIT 10.3 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement dated as of this May 22, 2012 (the “Agreement”), between GenVec, Inc., a Delaware corporation (the “Company”) and Paul H. Fischer, Ph.D., a resident of the State of Maryland (the “Executive”). NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and sufficient consideration,
May 10, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation) F
May 10, 2012	EX-99.1	GENVEC REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: Institutional Investor Contact: GenVec, Inc. S.A. Noonan Communications Douglas J. Swirsky Susan A. Noonan (240) 632-5510 (212) 966-3650 [email protected] [email protected] GENVEC REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS GA
March 15, 2012	EX-99.1	GENVEC REPORTS FOURTH QUARTER AND 2011 YEAR-END FINANCIAL RESULTS Exhibit 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 [email protected] Institutional Investor Contact: S.A. Noonan Communications Susan A. Noonan (212) 966-3650 [email protected] GENVEC REPORTS FOURTH QUARTER AND 2011 YEAR-END FINANC
March 15, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporation)
February 10, 2012	SC 13G/A	GNVC / GenVec, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 GenVec, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37246C 30 7 (CUSIP Number) December 31, 2011 (
January 27, 2012	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2012 GENVEC, INC. (Exact name of registrant as specified in its charter) Delaware 0-24469 23-2705690 (State or other jurisdiction (Commission (IRS Employer of Incorporatio
January 27, 2012	EX-99.1	GenVec Extends Research Collaboration with Global Pharmaceutical Company EXHIBIT 99.1 65 West Watkins Mill Road Gaithersburg, MD 20878 tel: 240-632-0740 fax: 240-632-0735 www.genvec.com FOR IMMEDIATE RELEASE Retail Investor and Media Contact: Institutional Investor Contact: GenVec, Inc. S.A. Noonan Communications Douglas J. Swirsky Susan A. Noonan (240) 632-5510 (212) 966-3650 [email protected] [email protected] GenVec Extends Research Collaboration with Global Phar

GNVC / GenVec, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)